NASDAQ:GANX Gain Therapeutics Q2 2025 Earnings Report $1.98 -0.09 (-4.35%) Closing price 04:00 PM EasternExtended Trading$1.94 -0.04 (-2.27%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gain Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.17Beat/MissMissed by -$0.02One Year Ago EPSN/AGain Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGain Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gain Therapeutics Earnings HeadlinesGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 15, 2026 | americanbankingnews.comGain Therapeutics' (GANX) Buy Rating Reiterated at BTIG ResearchAugust 14, 2026 | americanbankingnews.comChina Declares WarChina controls more than 90 percent of the world's refined rare earths and is quietly building a yuan-based payment network, gold vaults in Hong Kong, and cross-border trade deals designed to bypass the dollar. Meanwhile, a 13-nation pact signed inside the State Department and a flurry of executive orders suggest Trump may be resetting the dollar's foundation entirely, what analyst Porter Stansberry calls the Silicon Dollar, anchored to minerals, energy and AI infrastructure. The last dollar reset minted over a thousand new millionaires a day.August 20 at 1:00 AM | Porter & Company (Ad)Gain Therapeutics IncAugust 12, 2026 | money.usnews.comGain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate UpdateAugust 11, 2026 | markets.businessinsider.comGain Therapeutics (GANX) to Announce Quarterly Earnings on TuesdayAugust 10, 2026 | americanbankingnews.comSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects. Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity. In addition to its clinical program, the company is advancing preclinical pipelines targeting Parkinson’s disease and other central nervous system disorders. Using structure-based design and high-throughput screening, Gain seeks to expand its pipeline across multiple indications with high unmet medical need. Headquartered in Geneva, Switzerland, with research operations in Massachusetts, Gain Therapeutics was founded in 2015 and has since established collaborations with academic centers and industry partners to support its discovery and development efforts. The company is led by a management team with experience in biotechnology, pharmaceutical development, and protein science, guiding Gain through translational research toward clinical validation.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Walmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndSociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the ShowNasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineForget Chips: These 3 Stocks Are Building the AI Data Center BoomAnalog Devices’ AI Pivot Could Push Shares to Fresh Highs Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
